A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin

Overview

A study to assess the amount of drug in the blood of young to middle aged, healthy, male subjects after they received the final formulation of EC905 compared to solifenacin (Vesicare®) and tamsulosin OCAS (Omnic OCAS®). Subjects are given a single dose of the combination tablet EC905, Vesicare® and Omnic OCAS® in 3 separate periods.

Full Title of Study: “An Open-label, Randomized, Three-period Crossover, Single Dose Study to Compare the Pharmacokinetics of the Final EC905 Formulation to Marketed Solifenacin (Vesicare®) and Tamsulosin OCAS (Omnic OCAS®)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2010

Detailed Description

The subjects are randomized to one of 6 treatment sequence groups. Subjects are admitted to the clinical unit on Day -1 for pre-dose assessments. They remain in the clinic for two periods of 11 days and one period of 14 days. After randomization the subjects receive a single dose treatment on Day 1 followed by blood sampling for pharmacokinetic (PK) assessment. For both EC905 and Vesicare®, blood sampling continues for 10 days after dosing; for Omnic OCAS®, it continues for 3 days after dosing. Each period is separated by a wash-out period of at least 4 day, and subjects are checked for eligibility again one day prior to the start of a new dosing day. Vital signs, safety ECG measurements, safety laboratory assessments, adverse events and concomitant medications are monitored throughout the investigational period. A blood sample is drawn for CYP2D6 genotyping, in order to evaluate the effect of the CYP2D6 genotype on the PK of tamsulosin. Subjects return for an End of Study Visit (ESV) 7 days after the last on-site period, or after withdrawal.

Interventions

  • Drug: EC905
    • Oral
  • Drug: solifenacin
    • oral
  • Drug: tamsulosin
    • oral

Arms, Groups and Cohorts

  • Experimental: 1 combination tablet EC905
  • Experimental: 2: solifenacin
  • Experimental: 3: tamsulosin

Clinical Trial Outcome Measures

Primary Measures

  • The Pharmacokinetics (PK) of solifenacin after a single dose of the final formulation of the combination tablet EC905 with a single dose of Vesicare® and Omnic OCAS®
    • Time Frame: Predose to Day 10 after dosing (22 times)
    • AUClast (Area under the curve until last sample taken), Cmax (Maximum concentration)
  • The Pharmacokinetics (PK) of tamsulosin HCl after a single dose of the final formulation of the combination tablet EC905 with a single dose of Vesicare® and Omnic OCAS®
    • Time Frame: Predose to Day 10 after dosing (22 times)
    • AUClast (Area under the curve until last sample taken), Cmax (Maximum concentration)

Secondary Measures

  • The PK of solifenacin and tamsulosin HCl after a single dose of the final formulation of the combination tablet EC905 with a single dose of Vesicare® and Omnic OCAS®
    • Time Frame: Predose to Day 10 after dosing (22 times)
    • AUCinf (AUC extrapolated until infinity), t1/2 (Apparent terminal elimination half-life), tmax (Time to attain Cmax), CL/F (Apparent total body plasma clearance), Vz/F (Apparent volume of distribution)
  • Safety and tolerability of single doses of the final formulation combined EC905, marketed Vesicare® and marketed Omnic OCAS®
    • Time Frame: Screening to End of Study Visit (at least 7 days after the last on site period (treatment and PK sampling), or after withdrawal.)
    • Adverse events, clinical laboratory tests, vital signs, Electrocardiogram (ECG), physical examination

Participating in This Clinical Trial

Inclusion Criteria

  • Body Mass Index between 18.5 and 30.0 kg/m2, inclusive Exclusion Criteria:

  • Known or suspected hypersensitivity to solifenacin, tamsulosin, EC905, Vesicare, Omnic OCAS or any of the components of the formulations used. – Any of the contraindications or precautions for use as mentioned in the applicable sections of the SPC's of tamsulosin or solifenacin. – Use of grapefruit (more than 3 x 200 ml) or marmalade (more than three times) in the week prior to admission to the Clinical Unit, as reported by the subject. – Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Astellas Pharma Europe B.V.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Study Manager, Study Chair, Astellas Pharma Europe B.V.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.